15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Kiniksa Pharmaceuticals Ltd, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $60.00 to $107.00, a moderate spread. The average target of $87.38 sits 13% above the current $77.16. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.29 next quarter toward $1.62 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy00%
Buy8100%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Kiniksa Pharmaceuticals Ltd.
As of Sep, 7 of 7 firms rate KNSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
KNSA EPS & revenue forecast
EPS · NEXT QUARTER
$0.29
Range $0.23 – $0.33 · 4 analysts · +69% YoY
Next period, 4 analysts expect Kiniksa Pharmaceuticals Ltd to earn $0.29 a share (range $0.23 – $0.33), versus $0.17 a year earlier. Full-year consensus is $1.16, growing to $1.62 the year after.
REVENUE · NEXT QUARTER
$276.1M
Range $273.6M – $279.9M · 4 analysts · +37% YoY
Revenue is expected to reach $276.1M (range $273.6M – $279.9M), +36.6% year-over-year. Full-year consensus is $993.7M, rising to $1.2B next year.
Top analysts covering Kiniksa Pharmaceuticals Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on KNSA.
#1
David Nierengarten
Wedbush · Rank #66
Buy
$99.00+28.3% to target
Overall win rate
42%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #75
Buy
$107.00+38.7% to target
Overall win rate
51%
+ Follow
#3
Roger Song
Jefferies · Rank #101
Buy
$71.00-8.0% to target
Overall win rate
43%
+ Follow
#4
Paul Choi
Goldman Sachs
Buy
$90.00+16.6% to target
Coverage
—
+ Follow
#5
Geoff Meacham
Citigroup
Buy
$100.00+29.6% to target
Coverage
—
+ Follow
KNSA stock forecast FAQ
What is KNSA's average 12-month price target?+
The 8 analysts with a live target average $87.38 for Kiniksa Pharmaceuticals Ltd over the next 12 months, ranging from a $107.00 high to a $60.00 low.
Is KNSA stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for KNSA?+
The Street-high target is $107.00 (JP Morgan), and the Street-low is $60.00 (TD Cowen). The average of all 8 active targets is $87.38.
How many Wall Street analysts cover KNSA?+
8 analysts have an active rating on Kiniksa Pharmaceuticals Ltd, and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering KNSA?+
Among analysts who currently cover KNSA, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #66). Their current call is Buy with a $99.00 target.
What is Kiniksa Pharmaceuticals Ltd's projected EPS for next quarter?+
The consensus estimate is $0.29 per share (range $0.23 – $0.33) across 4 analysts. Full-year EPS is projected at $1.16, rising to $1.62 the following year.
How much revenue is Kiniksa Pharmaceuticals Ltd expected to report next quarter?+
Consensus revenue is $276.1M (range $273.6M – $279.9M). Full-year revenue is projected at $993.7M, growing to $1.2B next year.
Have analysts been upgrading or downgrading KNSA lately?+
As of Sep, 7 of 7 firms rate KNSA a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their KNSA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
